Tag archive for ‘Surfaxin LS’
Windtree Therapeutics: Discussion of Licensing Deal with Lee’s Pharmaceutical and Two Imminent Key Clinical Events (WINT, Buy, $0.90)
Introduction This report discusses a new licensing deal with Lee’s Pharmaceutical and alerts investors to two upcoming catalysts for the stock. In July, the critical results from the phase 2b trial of Aerosurf will be published. Before then in June, results from the phase 2a trial in babies of the 26 to 28 weeks will […]
Discovery Laboratories: The Street Is Getting on Board With Me
My Recent History on Discovery Laboratories On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at a price of $2.82; the report was called Surfaxin Should Be Approved on its March 6th PDUFA Date. I urged investors to buy the stock before the PDUFA date. When I issued the report, […]